Thursday, June 13, 2019 11:59:52 AM
Koffler said she attributes a 40% share selloff of the company's stock since April to financing uncertainty and the "lackluster" performance of the prescription anticholinergi Qbrexza.
"We believe Dermira could be strategically attractive to dermatology-focused companies," Koffler wrote. "We believe there could be significant cost synergies associated with cutting Qbrexza SG&A (Selling, General and Administrative Expenses)."
Koffler said that "the chief risk to our thesis is that Almirall walks away from EU rights."
"If Almirall abandons the deal, it may discourage other strategic interest in lebrikizumab as well," she wrote. "In this case, it's possible that Dermira would need to develop lebrikizumab on its own and pursue multiple financing rounds in the future against a limited catalyst calendar over the next three years while we await lebrikizumab approval and launch. Based on the pending Dermavant IPO focused on a Phase III psoriasis biologic, we believe the category is still attractive to investors and strategics and we view this scenario as unlikely."
Recent DERM News
- Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer • GlobeNewswire Inc. • 05/01/2024 08:01:30 PM
- Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 • GlobeNewswire Inc. • 04/25/2024 12:30:48 PM
- Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/21/2024 08:01:27 PM
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea • GlobeNewswire Inc. • 03/18/2024 12:30:30 PM
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/15/2024 12:30:01 PM
- Journey Medical Corporation to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/13/2024 12:30:14 PM
- Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:30:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:54:53 PM
- Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea • GlobeNewswire Inc. • 01/05/2024 01:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:05:34 PM
- Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million • GlobeNewswire Inc. • 01/02/2024 09:05:30 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/15/2023 09:46:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:01:17 PM
- Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea • GlobeNewswire Inc. • 12/06/2023 01:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:45:43 PM
- Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/07/2023 09:01:18 PM
- Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 • GlobeNewswire Inc. • 10/31/2023 12:30:12 PM
- Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) • GlobeNewswire Inc. • 10/20/2023 12:30:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2023 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 01:10:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2023 08:59:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/08/2023 05:26:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 12:00:22 PM
- Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations • GlobeNewswire Inc. • 09/06/2023 12:00:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/18/2023 09:00:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM